Straumann Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SAUHY research report →
Price Chart
About the company
Straumann Holding AG is a global leader in providing advanced solutions for tooth replacement and orthodontic treatment. The company actively researches, develops, manufactures, and distributes a comprehensive range of dental products and services designed for tooth correction, restoration, replacement, and the prevention of tooth loss. Its extensive portfolio includes various dental implant systems (such as titanium, titanium alloy, ceramic, and mini implants), specialized surgical instruments, sophisticated CAD/CAM prosthetics, and the Clear Correct orthodontic aligners.
- CEO
- Guillaume Daniellot
- IPO
- 2014
- Employees
- 11,824
- HQ
- Basel, BS, CH
Get TickerSpark's AI analysis on SAUHY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.85B
- P/E
- 45.82
- Fwd P/E
- 39.25
- PEG
- -8.08
- P/S
- 6.46
- P/B
- 7.47
- EV/EBITDA
- 25.01
- Div Yield
- 0.94%
- Gross Margin
- 68.38%
- Op Margin
- 20.89%
- Net Margin
- 14.05%
- ROE
- 16.68%
- ROIC
- 13.50%
Latest fiscal year · YoY change
- Revenue
- $2.61B+4.1%
- Gross Profit
- $1.69B-5.2%
- Op Income
- $513.75M
- Net Income
- $355.92M-8.3%
- EPS
- $0.21-10.8%
- OCF Growth
- -0.1%
- FCF Growth
- -0.2%
- 52W High
- $13.61
- 52W Low
- $9.44
- 50D MA
- $11.75
- 200D MA
- $11.69
- Beta
- 1.38
- RSI (14)
- 53
- Avg Volume
- 208.52K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Straumann Group delivered another strong quarter with 9.2% organic growth, broad regional momentum, and reaffirmed full-year guidance despite China VBP uncertainty and a volatile macro backdrop.· October 28, 2026
- Q3 revenue reached CHF 667.1 million, up 10.8% in Swiss francs and 9.2% organically; 9M revenue was just over CHF 2 billion, up 8.3% organically.
- EMEA and Asia Pacific were standout regions, with EMEA growing 10.5% organically and APAC 10.3% in Q3; North America also held up at 7.5% organic growth.
- Management said the scanner business, AXS platform adoption, and F.A.S.T workflows are improving mix, loyalty, and customer conversions.
- China returned to growth in Q3, but management flagged VBP 2.0 as an important unknown and said the commercial impact depends on the rules.
- Full-year 2026 guidance was reaffirmed: high single-digit organic revenue growth and core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates.
Third-quarter revenue was CHF 667.1 million, up 10.8% in Swiss francs and 9.2% organically. For the first 9 months, revenue was more than CHF 2 billion, up 4.9% in Swiss francs and 8.3% organically. By region in Q3, organic growth was 10.5% in EMEA, 7.5% in North America, 10.3% in Asia Pacific, and 6.5% in Latin America. Full-year 2026 guidance was confirmed for high single-digit organic revenue growth and core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates.
Guillaume Daniellot framed the quarter as evidence that Straumann is gaining share across implantology and digital dentistry despite a difficult macro environment. He emphasized the company’s 'perform and transform' strategy, saying the core implant business still has significant headroom while digital equipment, CAD/CAM prosthetics, and clear aligners remain underpenetrated relative to the opportunity. He was notably upbeat on innovation, citing iEXCEL, SIRIOS APS, AXS, and F.A.S.T as drivers of future growth and customer conversion.
Isabelle Adelt highlighted that 9M revenue exceeded CHF 2 billion, with currency effects being the main difference between organic growth and reported Swiss-franc growth. She said Q3 was the first quarter in a long time with a modest FX tailwind and estimated, using end-September spot rates, roughly 200 bps of top-line impact and 70 to 80 bps of EBIT impact for the full year, subject to Q4 FX moves. She also said the company expects to reduce its Swiss franc cost base by roughly 3 percentage points versus last year, with an isolated expectation of roughly 4 percentage points and further benefit to come from China after VBP.
Analysts focused heavily on the U.S. and China. Management said North American patient flow has stayed stable and that continued customer conversion, innovation, and strong execution should support healthy growth, while in China they described VBP 2.0 as early-stage and said the company has multiple ways to compete across price segments thanks to local manufacturing and a broader portfolio. On pricing, management said the expected China price effect is a blended 5% to 15% decline across the total portfolio, not a forecast for a single segment. They also clarified that the long-term 10% CAGR ambition was set with the Board and remains intact under current leadership.
The call pointed to broad-based share gains, with management saying the business is outperforming in a sluggish market through innovation and commercial execution. The scanner installed base has surpassed 65,000 units, AXS has more than 20,000 regular active users, and F.A.S.T Molar has already sold more than 100,000 abutments, suggesting early traction in connected workflows. Management also sounded confident that China, North America, and the 2027 product cycle can support continued growth.
China remains the biggest near-term uncertainty because VBP 2.0 rules are not yet known and could pressure pricing, even if management expects the net effect to be cushioned by private-market pricing and local manufacturing. Brazil also softened on election-related uncertainty, and management said they are watching revenue quality closely rather than chasing growth with weaker payment terms. In the U.S., management acknowledged cautious consumer sentiment and said not all consumer-driven dental demand has recovered, even though implant demand has remained more resilient.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 100.0%
- Shares Outstanding
- 1.59B
- Float Shares
- 1.59B
of shares held by institutions
7 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rhumbline Advisers | 80.30K | ▲ 1.14K |
| Westside Investment Management, Inc. | 702 | 0 |
| Pnc Financial Services Group, Inc. | 45 | 0 |
Held by 1 ETFs
Biggest fund positions in SAUHY by dollar value.
Our SAUHY coverage
Recent articles, reports, and earnings notes.
No research on SAUHY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SAUHY report →Straumann Holding AG (SAUHY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 28
Straumann (OTCMKTS:SAUHY) Shares Gap Up – Should You Buy?
defenseworld.net · Oct 12
Goldman Sachs names four 'must own' European stocks for 2027
invezz.com · Oct 3
Straumann (OTCMKTS:SAUHY) Stock Price Down 5.3% – Here’s Why
defenseworld.net · Oct 2
HSIC or SAUHY: Which Is the Better Value Stock Right Now?
zacks.com · Sep 16
HSIC vs. SAUHY: Which Stock Is the Better Value Option?
zacks.com · Aug 25
Straumann Holding AG (SAUHY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 19
HSIC or SAUHY: Which Is the Better Value Stock Right Now?
zacks.com · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.